ArticleDiscover oncology2025
Mendelian randomization analysis unveils causal associations between immune cells, metabolites, and lung cancer risk.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the leading cause of cancer-related deaths worldwide, with the highest incidence rates in the United States, posing significant public health challenges. Although treatment modalities have advanced to include chemotherapy, radiotherapy, targeted therapies, and immunotherapy, preventive strategies remain underdeveloped. Urgent research into preventive interventions is necessary due to the escalating prevalence of lung cancer, aiming to reduce both mortality rates and healthcare burden.
methodsThis study employed a Mendelian randomization approach using GWAS summary statistics of immunological features from the GWAS Catalogue to assess the potential causal relationship between T cell lymphocytes, celecoxib, and lung cancer risk. The analysis included various methods such as MR Egger, weighted median, inverse variance weighted, and simple mode to evaluate the robustness of these relationships.
resultsThe analysis revealed a significant association between T cell lymphocytes and lung cancer risk, particularly when using inverse variance weighted and simple mode methods (P-values of 0.002 and 0.000, respectively). The association between celecoxib and lung cancer risk also showed significance in weighted median and inverse variance weighted approaches (P-values of 0.014 and 0.001, respectively). Additionally, specific metabolites such as phosphatidylcholine and sphingolipids were significantly associated with lung cancer risk, potentially offering new biomarkers and targets for the prevention and treatment of lung cancer.
conclusionThis study, through Mendelian randomization analysis, unveiled causal relationships between T cell lymphocytes, celecoxib, and specific metabolites with lung cancer risk, providing new potential targets for the prevention and treatment of lung cancer that warrant further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.